Skip to content

Outcomes of Purpura FULminans in Adults - The hOPeFUL Study

Short and Long-term Outcomes of Purpura Fulminans in Adults

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03216577
Acronym
hOPeFUL
Enrollment
74
Registered
2017-07-13
Start date
2017-07-27
Completion date
2018-03-08
Last updated
2018-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Purpura Fulminans

Keywords

health-related quality of life

Brief summary

Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. The mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of limb amputation. The hOPeFUL study aims at assessing the short and long term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans.

Detailed description

Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. Neisseria meningitidis and Streptococcus pneumoniae are the most frequently involved microorganisms but other species (e.g., Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae…) have also been reported. Despite prompt antibiotics administration and intensive care management, the mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of serious sequelae related to extensive skin necrosis and acral symmetrical gangrene, which typically requires limb amputations, a potential source of severe handicap in these previously young and healthy patients. Although the clinical features and outcomes of PF have been well studied in the pediatric setting, the amount of available data for adult PF are scarce, often outdated and mainly limited to patients with meningococcal infections. The current study aims at assessing the short and long-term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans. A large multicenter retrospective cohort will be built in order to assess hospital outcomes (i.e., mortality and amputations). Long-term outcomes, including health-related quality variables, will be prospectively assessed among survivors and compared to septic controls (i.e., patients having septic shock non-related to purpura fulminans).

Interventions

OTHERPhone interview measuring health-related quality of life variables

A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.

Sponsors

Fondation de France
CollaboratorOTHER
Henri Mondor University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients admitted in the intensive care unit between 2010 and 2016 for an infectious purpura fulminans and discharged alive

Exclusion criteria

* Age \< 18 years * Non infectious purpura * Infective endocarditis

Design outcomes

Primary

MeasureTime frameDescription
Hospital mortalityday 60factors associated with hospital mortality (and rate of amputation in the hospital) will be identified using a polytomous logistic regression model
Rate of amputation in the hospital;day 60factors associated with rate of amputation in the hospital (and hospital mortality) will be identified using a polytomous logistic regression model
Long-term outcome measure: Physical dimension scale of the SF-36 questionnaireWithin 6 years of hospital dischargeThis variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

Secondary

MeasureTime frameDescription
Impact of Event ScaleWithin 6 years of hospital dischargeThis variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Mental component score of the SF-36 scoreWithin 6 years of hospital dischargeThis variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Physical dimension scale of the SF-36 questionnaireWithin 6 years of hospital dischargeThis variable will be compared between patients with purpura fulminans who were and those who were not amputated
Activity of daily living (ADL score)Within 6 years of hospital dischargeThis variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans
Hospital anxiety and depression scaleWithin 6 years of hospital dischargeThis variable will be compared between patients with purpura fulminans and patients with septic shock non-related to purpura fulminans

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026